oxybutynin Tablets 5 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
Morocco
GMP approvals
Morocco
Manufacturer #36891
Established in 2011, this CTD dossier owner and manufacturer has grown to become a leading GMP manufacturer, employing over 300 professionals. With GMP approvals in various regions, the manufacturer ensures high-quality standards across its production lines, specializing in solid and liquid dosage forms. Their products are sold in more than 50 countries and regions worldwide, showcasing their global reach as a CTD dossier owner and manufacturer. As a trusted GMP manufacturer, they maintain rigorous compliance to meet international regulations, reinforcing their commitment to quality and excellence in pharmaceutical manufacturing.
Oxybutynin is a medication used to treat overactive bladder. Suppliers market it as oxybutynin oral tablets, transdermal patches, topical gels and it is available as immediate and delayed-release formulations.
The drug was first approved for medical use in 1975, and by now has reached widespread use, with over 6 million prescriptions registered yearly in the U.S. alone. Multiple manufacturing companies and drug vendors populate the global oxybutynin market, including major suppliers such as Sanofi-Aventis, Mylan, Accord Healthcare, and many others.
Suppliers market both generic and trade name oxybutynin medications. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 60 (5mg) tablets of oxybutynin fall into an approximate range of 7.50 EUR to 10.00 EUR.